JP2013504577A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504577A5
JP2013504577A5 JP2012528860A JP2012528860A JP2013504577A5 JP 2013504577 A5 JP2013504577 A5 JP 2013504577A5 JP 2012528860 A JP2012528860 A JP 2012528860A JP 2012528860 A JP2012528860 A JP 2012528860A JP 2013504577 A5 JP2013504577 A5 JP 2013504577A5
Authority
JP
Japan
Prior art keywords
par
antigen
binding fragment
human
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012528860A
Other languages
English (en)
Japanese (ja)
Other versions
JP5832435B2 (ja
JP2013504577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/048034 external-priority patent/WO2011031695A1/en
Publication of JP2013504577A publication Critical patent/JP2013504577A/ja
Publication of JP2013504577A5 publication Critical patent/JP2013504577A5/ja
Application granted granted Critical
Publication of JP5832435B2 publication Critical patent/JP5832435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012528860A 2009-09-09 2010-09-08 ヒトプロテアーゼ活性化受容体−2に対する高親和性ヒト抗体 Expired - Fee Related JP5832435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US61/240,783 2009-09-09
US24282109P 2009-09-16 2009-09-16
US61/242,821 2009-09-16
US31783910P 2010-03-26 2010-03-26
US61/317,839 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015177339A Division JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−2に対する高親和性ヒト抗体

Publications (3)

Publication Number Publication Date
JP2013504577A JP2013504577A (ja) 2013-02-07
JP2013504577A5 true JP2013504577A5 (https=) 2013-09-05
JP5832435B2 JP5832435B2 (ja) 2015-12-16

Family

ID=43063654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012528860A Expired - Fee Related JP5832435B2 (ja) 2009-09-09 2010-09-08 ヒトプロテアーゼ活性化受容体−2に対する高親和性ヒト抗体
JP2015177339A Expired - Fee Related JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−2に対する高親和性ヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015177339A Expired - Fee Related JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−2に対する高親和性ヒト抗体

Country Status (29)

Country Link
US (3) US8101724B2 (https=)
EP (1) EP2475684B1 (https=)
JP (2) JP5832435B2 (https=)
KR (1) KR101766701B1 (https=)
CN (1) CN102574923B (https=)
AR (1) AR078346A1 (https=)
AU (1) AU2010292342C1 (https=)
BR (1) BR112012005338A2 (https=)
CA (1) CA2773541A1 (https=)
CY (1) CY1118714T1 (https=)
DK (1) DK2475684T3 (https=)
ES (1) ES2609780T3 (https=)
HR (1) HRP20170324T1 (https=)
HU (1) HUE031725T2 (https=)
IL (1) IL218501A (https=)
JO (1) JO3246B1 (https=)
LT (1) LT2475684T (https=)
MX (1) MX2012002927A (https=)
MY (1) MY159551A (https=)
NZ (1) NZ599204A (https=)
PL (1) PL2475684T3 (https=)
PT (1) PT2475684T (https=)
SG (1) SG178976A1 (https=)
SI (1) SI2475684T1 (https=)
SM (2) SMT201700102T1 (https=)
TW (1) TWI492757B (https=)
UY (1) UY32883A (https=)
WO (1) WO2011031695A1 (https=)
ZA (1) ZA201201730B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017083618A1 (en) * 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗pd1および抗ctla4抗体
MX2019010802A (es) * 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CA3136281C (en) * 2019-05-30 2024-06-25 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
CN114599351A (zh) * 2019-11-01 2022-06-07 株式会社资生堂 以皮肤中的活性型par-2为指标的皮肤状态评价方法、par-2激活促进剂或抑制剂的筛选方法和par-2激活抑制剂
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
CA3173205A1 (en) * 2020-03-31 2021-10-07 Roland B. WALTER Human anti-cd33 antibodies and uses thereof
SMT202500106T1 (it) 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
AU2022340645A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Anti-cd33 antibodies and uses thereof
AU2022340644A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting cd33 and uses thereof
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
KR101360708B1 (ko) 2009-06-18 2014-02-07 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 화장료 조성물
JP2012530699A (ja) 2009-06-18 2012-12-06 株式会社アモーレパシフィック 栗皮抽出物を含む健康食品又は薬学組成物
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Similar Documents

Publication Publication Date Title
JP2013504577A5 (https=)
JP2026016421A (ja) 炎症性状態の処置方法
CN103946240B (zh) 对人ox40具有特异性的抗体分子
CN101379085B (zh) Il-12/p40结合蛋白
JP2022526738A5 (https=)
Smith et al. Painful rheumatoid arthritis
HRP20170324T1 (hr) Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor
TW200831533A (en) Interleukin-13 binding proteins
JP2010043089A5 (https=)
TW201233395A (en) Methods for treating psoriasis
JP2019534282A (ja) 抗il−33抗体およびその使用
JP2013543382A (ja) 破骨細胞関連蛋白質Siglec−15を標的とした抗体
JP2025102888A (ja) Il-17アンタゴニストを用いて初発プラーク型乾癬を治療する方法
TW201513883A (zh) 治療牛皮癬的方法
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
McDermott Rilonacept in the treatment of chronic inflammatory disorders
KR20240052084A (ko) 조합 및 이의 용도
AU2019269131B2 (en) Antibodies against LIF and dosage forms thereof
JP6663910B2 (ja) 抗TNF−α抗体療法を受けた乾癬患者を治療するための方法
EP3322725A1 (en) Treatment of pruritus
JP2022534794A5 (https=)
US20160136272A1 (en) Methods for restoring corticosteroid sensitivity
Dimov et al. Immunomodulators for asthma
JP2023527200A5 (https=)
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体